menu
    • menu

    Company profile for AcelRx Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company’s product candidates, DSUVIA™ (known as D...
    AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company’s product candidates, DSUVIA™ (known as DZUVEO outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AcelRx PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    351 Galveston Drive, Redwood City, CA 94063
    Telephone
    Telephone
    650-216-3500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.acelrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/acelrx-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AcelRx becomes Talphera, adopting new name to reflect pain pivot
    AcelRx becomes Talphera, adopting new name to reflect pain pivot

    10 Jan 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot

    FIERCE PHARMA
    10 Jan 2024
    Share Share
    AcelRx Announces Rebranding With Name Change to Talphera, Inc.
    AcelRx Announces Rebranding With Name Change to Talphera, Inc.

    09 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acelrx-announces-rebranding-with-name-change-to-talphera-inc-302029288.html

    PR NEWSWIRE
    09 Jan 2024
    Share Share
    AcelRx Announces Publication of Study Evaluating Anticoagulation Practices
    AcelRx Announces Publication of Study Evaluating Anticoagulation Practices

    12 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-publication-of-study-evaluating-anticoagulation-practices-for-continuous-renal-replacement-therapy--in-the-united-states-302012467.html

    PR NEWSWIRE
    12 Dec 2023
    Share Share
    AcelRx Reports Third Quarter 2023 Financial Results
    AcelRx Reports Third Quarter 2023 Financial Results

    08 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acelrx-reports-third-quarter-2023-financial-results-and-provides-corporate-update-301982149.html

    PR NEWSWIRE
    08 Nov 2023
    Share Share
    AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis
    AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis

    07 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acelrx-to-host-kol-panel-discussion-on-current-anticoagulant-use-in-dialysis-and-the-upcoming-niyad-clinical-study-301980608.html

    PR NEWSWIRE
    07 Nov 2023
    Share Share
    AcelRx to Host Third Quarter 2023 Financial Results Call
    AcelRx to Host Third Quarter 2023 Financial Results Call

    26 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acelrx-to-host-third-quarter-2023-financial-results-call-and-webcast-on-november-8-2023-301969382.html

    PR NEWSWIRE
    26 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search